Cancer peptide vaccine therapy for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.

Cancer peptide vaccine therapy for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial. - Cancer peptide vaccine for advanced metastatic colorectal cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004945

Enrollment

Registered

2011-01-25

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Subcutaneous injection of cancer peptide vaccines (five peptides)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Standard therapies failured 2 Performance status 0-2 3 Lesions identifiable with images 4 More than 4 weeks after previous therapy 5 Prognosis no less than 3 months 6 WBC 2000 -15000, Platelet =>75000, GOT, GPT =< 3 times, Cr =< 2.0 7 HLA-A24 positive 8 Written informed consent

Exclusion criteria

Exclusion criteria: 1 Cardiac diseases necessitating treatments 2 Myocardial infarction less than 6 months 3 Expectant or possible expectant women During lactation 4 Active infectious diseases 5 Systemic use of steroid hormones or immunosuppressive drugs 6 Allergy to peptides or IFA 7 Others (Doctors judges)

Design outcomes

Primary

Measure	Time frame
Safety Responsiveness (tumor size)	—

Secondary

Measure	Time frame
Immunological response (in vitro CTL induction)	—

Countries

Japan

Contacts

Public ContactSeiei Yasuda

Tokai University School of Medicine Department of Surgery

yasuda@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026